Table 2. Clinical data of first-line patients responding to the therapy.
| Pat ID | Smoking status / pack years | Histology | Stage (UICC/AJCC) |
|---|---|---|---|
| UKH 007 | ex-smoker / 35 | SCLC | IV |
| UKH 012 | yes / 42 | SCLC | IV |
| UKH 015 | ex-smoker / 17 | Adenocarcinoma | IV |
| UKH 022 | ex-smoker / 35 | undifferentiated carcinoma | IV |
| UKH 025 | ex-smoker / 25 | SCLC | IV |
| UKH 026 | yes / 40 | Adenocarcinoma | IIIB |
| UKH 029 | ex-smoker / 29 | Adenocarcinoma | IV |
| UKH 030 | yes / 33 | Adenocarcinoma | IV |
| UKH 031 | never | Adenocarcinoma | IV |
| UKH 034 | ex-smoker / 15 | Adenocarcinoma | IV |
| UKH 040 | never | Adenocarcinoma | IV |
| UKH 042 | ex-smoker / 33 | Sqamous cell carcinoma | IV |
Ten of the patients were male and two were female. The median age of this patient group is 61.5 years. Patient UKH 031 demonstrated an EGFR mutation and was treated with TKI.